923-27-3
Chemical Structure
D-Lysine
- CAS No.: 923-27-3
- Formula:C6H14N2O2
- Molecular Weight:146.19
IUPAC Name: D-lysine
InChIKey: KDXKERNSBIXSRK-RXMQYKEDSA-N
SMILES: N[C@H](CCCCN)C(O)=O
Biological Activity: D-Lysine is the D-enantiomer of L-Lysine (HY-N0469). D-Lysine is metabolically inert and not utilized for protein synthesis by mammalian ribosomes. D-Lysine blocks renal uptake of 111In/90Y-Octreotide (HY-P0036)-based probes without inhibiting uptake by tumor/receptor tissues, and thus acts as a renoprotective agent in diagnostic imaging and peptide receptor radionuclide therapy (PRRT). D-Lysine specifically inhibits the early steps of non-enzymatic glycation by competing with glucose via its free amino group, theoretically, it can serve as a glycation competitor that "does not interfere with protein synthesis" under chronic hyperglycemia in diabetes. D-Lysine can be used in research related to cancer and diabetes[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
D-Lysine | 99.91% | D-Lysine is the D-enantiomer of L-Lysine (HY-N0469). D-Lysine is metabolically inert and not utilized for protein synthesis by mammalian ribosomes. D-Lysine blocks renal uptake of 111In/90Y-Octreotide (HY-P0036)-based probes without inhibiting uptake by tumor/receptor tissues, and thus acts as a renoprotective agent in diagnostic imaging and peptide receptor radionuclide therapy (PRRT). D-Lysine specifically inhibits the early steps of non-enzymatic glycation by competing with glucose via its free amino group, theoretically, it can serve as a glycation competitor that "does not interfere with protein synthesis" under chronic hyperglycemia in diabetes. D-Lysine can be used in research related to cancer and diabetes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
